Levofloksacin Kabi (Levofloxacin Hemihydrate)

Levofloxacin blocks bacterial DNA gyrase and topoisomerase IV, enzymes that unwind and reseal DNA during replication and transcription. By preventing these processes, the drug induces bacterial cell death. This mechanism provides broad‑spectrum, concentration‑dependent bactericidal activity against many Gram‑positive and Gram‑negative organisms.

The specific dose and infusion rate of Levofloksacin Kabi are determined by the prescribing clinician based on the infection type, severity, patient weight, renal function, and local guidelines. Healthcare professionals tailor the regimen to achieve optimal therapeutic outcomes while minimizing toxicity.

Safety data for levofloxacin in pregnancy and lactation are limited, and the drug is generally classified as contraindicated or used only when the potential benefit outweighs the risk. Clinicians should evaluate the maternal‑fetal risk and consider alternative agents when possible.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Levofloxacin is a third‑generation fluoroquinolone with enhanced activity against Gram‑negative pathogens and a favorable pharmacokinetic profile that allows once‑daily dosing in oral formulations. Compared with older agents like ciprofloxacin, levofloxacin often achieves higher tissue concentrations and broader coverage, but safety considerations such as tendon toxicity remain similar across the class.

Levofloksacin Kabi should be stored at controlled room temperature, typically below 25 °C, in its original packaging. The product must be protected from excessive light, moisture, and physical damage to maintain stability until administration.

Levofloksacin Kabi is supplied as an intravenous solution and is administered by slow infusion into a peripheral or central vein. The infusion rate and duration are set by the treating physician, who monitors the patient for clinical response and potential adverse effects during and after the infusion.

Serious risks include tendon rupture or tendinitis, especially in older adults; QT interval prolongation leading to cardiac arrhythmias; severe hypersensitivity reactions such as anaphylaxis or Stevens‑Johnson syndrome; Clostridioides difficile‑associated colitis; and peripheral neuropathy. Prompt recognition and discontinuation are essential if these events occur.

Patients with a known hypersensitivity to levofloxacin or any fluoroquinolone should avoid the drug. It is also contraindicated in individuals with a history of tendon disorders related to fluoroquinolone use, those with significant QT prolongation, and patients with severe renal impairment without appropriate dose adjustment.